Publicacións en colaboración con investigadores/as de Hospital Infanta Leonor (20)

2024

  1. Effectiveness of Treatment Approaches in COVID-19 Pneumonia: A Comparative Evaluation between a Specialized Center and Conventional Hospitals

    Healthcare (Switzerland), Vol. 12, Núm. 14

  2. Impact of systemic therapies on SARS-CoV-2 antibody seroprevalence in patients with immune-mediated diseases

    Medicina Clinica, Vol. 162, Núm. 10, pp. 470-476

2023

  1. AB1352 Impact of Systemic Therapies on the Seroprevalence of Sars-Cov-2 in Patients with Immune-Mediated Diseases

    Annals of the Rheumatic Diseases, Vol. 82, Núm. Suppl 1, pp. 1907.1-1907

  2. COVID-19 Severity and Survival over Time in Patients with Hematologic Malignancies: A Population-Based Registry Study

    Cancers, Vol. 15, Núm. 5

  3. Seroprevalence of SARS-CoV-2 antibodies in patients with immune-mediated inflammatory diseases treated with biological and synthetic targeted therapies

    Revista Chilena de Infectologia, Vol. 40, Núm. 6, pp. 618-625

2022

  1. Early predictive risk factors for dimethyl fumarate-associated lymphopenia in patients with multiple sclerosis

    Multiple Sclerosis and Related Disorders, Vol. 59

  2. Incidence of COVID-19 in 902 Patients With Immunomediated Inflammatory Diseases Treated With Biologics and Targeted Synthetic Disease-Modifying Antirheumatic Drugs-Findings From the BIOCOVID Study

    Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases, Vol. 28, Núm. 2, pp. e348-e352

  3. Incidence of COVID-19 in 902 Patients With Immunomediated Inflammatory Diseases Treated With Biologics and Targeted Synthetic Disease-Modifying Antirheumatic Drugs—Findings From the BIOCOVID Study

    JCR: Journal of Clinical Rheumatology, Vol. 28, Núm. 2, pp. e348-e352

2021

  1. Impact of biological therapies on the immune response after pneumococcal vaccination in patients with autoimmune inflammatory diseases

    Vaccines, Vol. 9, Núm. 3, pp. 1-12

  2. Measuring Choroid Thickness as a Marker of Systemic Inflammation in Patients with Ankylosing Spondylitis

    Journal of Clinical Rheumatology, Vol. 27, Núm. 8, pp. E307-E311

2020

  1. AB0726 Choroidal Thickness Is a Biomarker a and Can Predict The Response to Treatment in Ankylosing Spondylitis

    Annals of the Rheumatic Diseases, Vol. 79, Núm. Suppl 1, pp. 1657.1-1658

  2. Choroidal Thickness Is a Biomarker Associated With Response to Treatment in Ankylosing Spondylitis

    JCR: Journal of Clinical Rheumatology

  3. Comparison of noninvasive cardiac test strategies for newly diagnosed chagas disease in a non-endemic zone

    American Journal of Tropical Medicine and Hygiene, Vol. 103, Núm. 4, pp. 1480-1486

  4. Evaluation of the immune response to hepatitis B vaccine in patients on biological therapy: results of the RIER cohort study

    Clinical Rheumatology, Vol. 39, Núm. 9, pp. 2751-2756

  5. Impact of hematologic malignancy and type of cancer therapy on COVID-19 severity and mortality: Lessons from a large population-based registry study

    Journal of Hematology and Oncology, Vol. 13, Núm. 1

  6. Three-Year Effectiveness of Dimethyl Fumarate in Multiple Sclerosis: A Prospective Multicenter Real-World Study

    CNS Drugs, Vol. 34, Núm. 12, pp. 1275-1286

  7. Tolerability and safety of dimethyl fumarate in relapsing multiple sclerosis: a prospective observational multicenter study in a real-life Spanish population

    Journal of Neurology, Vol. 267, Núm. 8, pp. 2362-2371

2019

  1. Antibody responses to influenza vaccine in patients on biological therapy: Results of RIER cohort study

    Medicina Clinica, Vol. 153, Núm. 10, pp. 380-386

2018

  1. Spanish National Hip Fracture Registry (SNHFR): a description of its objectives, methodology and implementation

    Revista Espanola de Geriatria y Gerontologia, Vol. 53, Núm. 4, pp. 188-195

2016

  1. Anti-JC virus seroprevalence in a Spanish multiple sclerosis cohort JC virus seroprevalence in Spain

    Journal of the Neurological Sciences, Vol. 365, pp. 16-21